Kuriyama Naohisa, Isaji Shuji, Hamada Takashi, Kishiwada Masashi, Ohsawa Ichiro, Usui Masanobu, Sakurai Hiroyuki, Tabata Masami, Suzuki Koji, Uemoto Shinji
Department of Hepatobiliary Pancreatic Surgery, Mie University Graduate School of Medicine, Mie, Japan.
Liver Int. 2009 Feb;29(2):299-307. doi: 10.1111/j.1478-3231.2008.01796.x. Epub 2008 May 26.
Hepatic ischaemia-reperfusion injury (IRI) is a serious complication of liver surgery, especially extended hepatectomy and liver transplantation. Activated protein C (APC), a potent anticoagulant serine protease, has been shown to have cell-protective properties by virtue of its anti-inflammatory and anti-apoptotic activities.
The present study was designed to examine the cytoprotective effects of APC in a 60-min warm-IRI rat model.
Following a single intravenous injection of APC before reperfusion, APC exerted cytoprotective effects 4 h after reperfusion, as evidenced by: (i) decreased levels of transaminase and improved histological findings of IRI, (ii) reduced infiltration and activation of neutrophils, macrophages and T cells, (iii) reduced expression of tumour necrosis factor-alpha, (iv) reduced expression of P-selectin and intracellular adhesion molecule-1, (v) inhibited coagulation and attenuated sinusoidal endothelial cell injury, (vi) improved hepatic microcirculation and (vii) decreased transferase-mediated dUTP nick end-labelling-positive cells. These effects of APC were observed 4 h but not 24 h after reperfusion. However, multiple injections of APC after reperfusion significantly decreased the levels of transaminase and the activity of myeloperoxidase, and improved histological findings of IRI 24 h after reperfusion.
These results suggest that APC is a promising therapeutic option for hepatic warm-IRI; however, multiple injections of APC are necessary to maintain its cell-protective action over the long term.
肝缺血再灌注损伤(IRI)是肝脏手术尤其是扩大肝切除术和肝移植的严重并发症。活化蛋白C(APC)是一种强效抗凝丝氨酸蛋白酶,已显示因其抗炎和抗凋亡活性而具有细胞保护特性。
本研究旨在检测APC在60分钟热缺血再灌注大鼠模型中的细胞保护作用。
在再灌注前单次静脉注射APC后,APC在再灌注后4小时发挥细胞保护作用,表现为:(i)转氨酶水平降低,IRI的组织学表现改善;(ii)中性粒细胞、巨噬细胞和T细胞的浸润及活化减少;(iii)肿瘤坏死因子-α表达降低;(iv)P-选择素和细胞间黏附分子-1表达降低;(v)凝血受抑制,肝血窦内皮细胞损伤减轻;(vi)肝微循环改善;(vii)转移酶介导的dUTP缺口末端标记阳性细胞减少。APC的这些作用在再灌注后4小时而非24小时观察到。然而,再灌注后多次注射APC可显著降低转氨酶水平和髓过氧化物酶活性,并改善再灌注后24小时IRI的组织学表现。
这些结果表明,APC是肝热缺血再灌注损伤的一种有前景的治疗选择;然而,需要多次注射APC以长期维持其细胞保护作用。